Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) insider Justin Burgess sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $10.00, for a total value of $60,000.00. Following the transaction, the insider now owns 3,854 shares in the company, valued at $38,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Justin Burgess also recently made the following trade(s):
- On Thursday, March 3rd, Justin Burgess sold 21,490 shares of Dynavax Technologies stock. The shares were sold at an average price of $10.58, for a total value of $227,364.20.
Dynavax Technologies stock opened at $9.62 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.64 and a current ratio of 1.75. The business’s 50-day simple moving average is $10.15 and its 200-day simple moving average is $12.67. The firm has a market capitalization of $1.22 billion, a PE ratio of 17.49 and a beta of 1.44. Dynavax Technologies Co. has a 52 week low of $7.26 and a 52 week high of $21.39.
Several research firms have weighed in on DVAX. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. TheStreet upgraded Dynavax Technologies from a “d+” rating to a “c” rating in a report on Wednesday, March 30th. Finally, Zacks Investment Research lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Dynavax Technologies currently has an average rating of “Hold” and an average target price of $21.00.
A number of hedge funds have recently added to or reduced their stakes in DVAX. Marshall Wace LLP boosted its holdings in Dynavax Technologies by 225.0% during the first quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 11,387 shares in the last quarter. Invesco Ltd. boosted its holdings in Dynavax Technologies by 48.6% during the second quarter. Invesco Ltd. now owns 39,236 shares of the biopharmaceutical company’s stock valued at $386,000 after purchasing an additional 12,838 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Dynavax Technologies by 172.5% during the second quarter. Wells Fargo & Company MN now owns 168,815 shares of the biopharmaceutical company’s stock valued at $1,663,000 after purchasing an additional 106,872 shares in the last quarter. Morgan Stanley boosted its holdings in Dynavax Technologies by 176.1% during the second quarter. Morgan Stanley now owns 1,789,695 shares of the biopharmaceutical company’s stock valued at $17,629,000 after purchasing an additional 1,141,462 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in Dynavax Technologies by 51.3% during the third quarter. Advisor Group Holdings Inc. now owns 50,044 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 16,964 shares in the last quarter. 76.80% of the stock is currently owned by institutional investors and hedge funds.
Dynavax Technologies Company Profile (Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
- Get a free copy of the StockNews.com research report on Dynavax Technologies (DVAX)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.